Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial

This publication has 41 references indexed in Scilit:

• Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis
  Transplantation and Cellular Therapy, 2018
• Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
  New England Journal of Medicine, 2017
• Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis
  Journal of Clinical Investigation, 2017
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
  Transplantation and Cellular Therapy, 2015
• Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
  Blood, 2015
• Expression of α4β7 integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD
  Bone Marrow Transplantation, 2012
• CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
  Cancer Research, 2012
• Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer
  The Journal of Immunology, 2009
• LPAM (α4β7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease
  Blood, 2004
• Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction
  Nature Immunology, 2003